Lipidica, a.s.
Lipidica, a.s. is a spin-off company focused on developing and promoting non-invasive, early diagnosis of malignant neoplasms, primarily pancreatic cancer. Their core product, the LPDC Lipidomic test, utilizes lipidome analysis coupled with mathematical modeling and AI algorithms to detect pancreatic cancer at early, treatable stages. The company is conducting a clinical study in the Czech Republic to validate this non-invasive blood test. Lipidica holds patents for its early detection method in the EU, US, Singapore, and Japan. The company is also certified under EN ISO 13485:2016 and ČSN EN ISO 15189 ed. 3:2023 for its laboratory practices. Their business model involves clinical validation and implementation of the LPDC test into clinical practice, with plans to extend the method to other cancer types.
Lipidica, a.s.
Lipidica, a.s. is a spin-off company focused on developing and promoting non-invasive, early diagnosis of malignant neoplasms, primarily pancreatic cancer. Their core product, the LPDC Lipidomic test, utilizes lipidome analysis coupled with mathematical modeling and AI algorithms to detect pancreatic cancer at early, treatable stages. The company is conducting a clinical study in the Czech Republic to validate this non-invasive blood test. Lipidica holds patents for its early detection method in the EU, US, Singapore, and Japan. The company is also certified under EN ISO 13485:2016 and ČSN EN ISO 15189 ed. 3:2023 for its laboratory practices. Their business model involves clinical validation and implementation of the LPDC test into clinical practice, with plans to extend the method to other cancer types.